This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
4
mifepristone at doses from 300mg/day up to 1200mg/day
The Center for Diabetes and Endocrine Care
Hollywood, Florida, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Number of Participants With Adverse Events
Safety was assessed at all visits and adverse events were recorded.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Ohio State University, Division of Endocrinology Diabetes and Metabolism
Columbus, Ohio, United States